Morgan Stanley Maintains Overweight on ADC Therapeutics, Lowers Price Target to $47
Morgan Stanley maintains ADC Therapeutics (NYSE:ADCT) with a Overweight and lowers the price target from $51 to $47.
ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty
ADC Therapeutics SA (NYSE:ADCT) has entered into a royalty purchase agreement with HealthCare Royalty Partners for up to $325 million. ADC Therapeutics will…
RBC Capital Initiates Coverage On ADC Therapeutics with Outperform Rating, Announces Price Target of $33
RBC Capital analyst Kennen MacKay initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Outperform rating and announces Price Target of $33.
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly’s Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 2)
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
Morgan Stanley Maintains Overweight on ADC Therapeutics, Lowers Price Target to $51
Morgan Stanley analyst Matthew Harrison maintains ADC Therapeutics (NYSE:ADCT) with a Overweight and lowers the price target from $53 to $51.
ADC Therapeutics Highlights Interim Results From Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine Presented At 16th Annual International Conference On Malignant Lymphoma
ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that
ADC Therapeutics Highlights Presentation Of Updated ZYNLONTA Clinical Data At 16th Annual International Conference On Malignant Lymphoma
LOTIS-2 updated results demonstrate durable responses of ZYNLONTA™ with median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL
LOTIS-3 updated Phase 1